Navigation Links
Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases
Date:9/21/2009

THOUSAND OAKS, Calif., Sept. 21 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced detailed results from a Phase 3 trial evaluating denosumab administered subcutaneously versus Zometa(R) (zoledronic acid) administered as an intravenous infusion in the treatment of bone metastases in 1,776 advanced cancer patients with solid tumors (not including breast and prostate cancer) or multiple myeloma. These results were presented today at the 2009 ECCO 15 - ESMO 34 European Multidisciplinary Congress in Berlin, Germany (Abstract Number: 20LBA).

For the primary endpoint of this study, the median time to first on-study skeletal related event (SRE) (fracture, radiation to bone, surgery to bone, or spinal cord compression) was 20.6 months for those patients receiving denosumab and 16.3 months for those patients receiving Zometa (hazard ratio 0.84, 95 percent CI: 0.71-0.98), which is statistically significant for non-inferiority (p=0.0007). Although numerically greater, the delay in the time to first SRE associated with denosumab was not statistically superior compared to Zometa based upon the statistical testing strategy (adjusted p=0.06) (secondary endpoint). The time to first-and-subsequent SRE was also numerically greater but not statistically superior compared to Zometa (hazard ratio 0.90, 95 percent CI: 0.77-1.04, p=0.14) (secondary endpoint).

"It is encouraging to see denosumab's efficacy in this broad cancer population. There is no need for renal monitoring or dose adjustments due to renal impairment," said David Henry, M.D., clinical professor of Medicine, Pennsylvania Hospital, Philadelphia, PA, United States of America. "Furthermore, the positive results of this study, combined with the convenience of a monthly subcutaneous injection and without the fl
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
(Date:1/14/2014)... , Jan. 14, 2014 HeartWare International, Inc ... of less invasive, miniaturized circulatory support technologies that are ... that it expects revenues for the fourth quarter of ... 2013 revenues to approximately $208 million. "Our ...
(Date:1/14/2014)... North America,s leading business partnering event ... 30 th edition of its annual conference at the ... 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... specialty chemical companies will take part in the conference, which ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... July 19, 2011 Spanish drug companies face a ... the United States.  From regulatory (FDA) and GMP compliance, ... there are many areas that must be coordinated.  Those ... company KIM and U.S. company VPCI have entered into ...
... July 19, 2011 Reportlinker.com announces that ... in its catalogue: The ... Discovery http://www.reportlinker.com/p0574968/The-Changing-Role-of-Natural-Products-in-Drug-Discovery.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development ... This report reveals how natural products have ...
Cached Medicine Technology:Spanish Drug Companies Have New Support Option for the U.S. Market 2The Changing Role of Natural Products in Drug Discovery 2The Changing Role of Natural Products in Drug Discovery 3The Changing Role of Natural Products in Drug Discovery 4
(Date:4/24/2014)... WINSTON-SALEM, N.C. April 24, 2014 ,Take me ... of apple slices and kale chips. The more likely ... of Crackerjacks. , Unfortunately for children who play ... may be contributing to weight problems, according to researchers ... in the current online edition of Childhood Obesity ...
(Date:4/24/2014)... Richard Plemper, a professor in the new Institute ... received a five-year, $2.83 million federal grant to ... infection. , The grant from the Eunice Kennedy ... Development of the National Institutes of Health will ... anti-RSV drug and at least one distinct alternative ...
(Date:4/24/2014)... epidemic of prescription opioid overdose deaths was outlined yesterday ... by leaders of agencies in the U.S. Department of ... health care providers to expand their use of medications ... describes a number of misperceptions that have limited access ... how medications can be used in combination with behavior ...
(Date:4/24/2014)... the first in the world to discover a gene ... jaw. , Ameloblastoma is an odontogenic tumour with a ... often found in the posterior of the lower jaw. ... deficiencies in the jaws as well as loss of ... need for surgery and the recurrence of ameloblastoma, but ...
(Date:4/24/2014)... Foundation has awarded LSU Health Sciences Center New ... grant in the amount of $295,635. The funding ... social and educational backgrounds, underrepresented in the sciences, ... project will provide students with training for 10 ... will be led by Principal Investigator Dr. Fern ...
Breaking Medicine News(10 mins):Health News:Take the bat, leave the candy 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 3Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 4
... twins found that exposure to trichloroethylene (TCE) -- a ... -- is significantly associated with increased risk of Parkinson,s ... also linked to perchloroethylene (PERC) and carbon tetrachloride (CCI4) ... Annals of Neurology , a journal published by Wiley-Blackwell ...
... of the brain responsible for pain processing and ... following a medication holiday, say researchers from Georgetown ... indicate brain functioning is more streamlined after an ... is devoted to processing bothersome fibromyalgia perceptions such ...
... Diego School of Medicine and the UC San Diego ... approach enabling the destruction of the most highly proliferative ... issue of the journal Nature Medicine , points ... cells without causing some of the negative effects of ...
... , SUNDAY, Nov. 13 (HealthDay News) -- Unborn ... the heart transplant list before birth get new hearts more ... study. The findings are to be presented Tuesday ... After reviewing cases of fetal heart patients, including 46 ...
... , FRIDAY, Nov. 11 (HealthDay News) -- All ... be screened for high cholesterol, according to new guidelines endorsed ... are a major shift from current guidelines that suggest such ... history of heart disease or high blood cholesterol, which is ...
... will soon reduce reimbursements to some dialysis facilities, ... to drive further to get care at other ... People initiative provides 10-year national objectives for improving ... presents new kidney-related objectives., Two studies presented ...
Cached Medicine News:Health News:Parkinson's disease risk greater in those exposed to trichloroethylene 2Health News:Improved memory efficiency seen after aerobic exercise in fibromyalgia patients 2Health News:New way to target - and kill - proliferating tumors 2Health News:Babies Put on Transplant List Before Birth Get Hearts Faster 2Health News:New Guidelines Urge Cholesterol Check for All Kids Ages 9 to 11 2Health News:New Guidelines Urge Cholesterol Check for All Kids Ages 9 to 11 3Health News:New Guidelines Urge Cholesterol Check for All Kids Ages 9 to 11 4Health News:Kidney disease care -- what's in store for the future? 2
Mayfield Disposable Adult (plastic) Skull Pins are designed for rigid skeletal fixation....
... borescopes are rigid endoscopes for general applications and ... The diameters of borescopes, i.e. rigid endoscopes, range ... directions from 0 up to a 120 retrospection, ... and wide angle view. Endoscopes with working lengths ...
Long system ventriculoscope for stereotactic frames....
... a new biological material produced ... collagen implant, lyoplant can absorb ... replacing implant material with the ... structure minimizes suture channels, resulting ...
Medicine Products: